Published in Ophthalmologe on December 01, 2003
Outcome of penetrating keratoplasty in corneal ulcer: a single-center experience. Clin Ophthalmol (2011) 0.88
Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol (2006) 0.87
[Immune suppression following perforating keratoplasty]. Ophthalmologe (2007) 0.81
Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty. Graefes Arch Clin Exp Ophthalmol (2015) 0.76
[Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe]. Ophthalmologe (2005) 0.75
[Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation]. Ophthalmologe (2014) 0.75
[Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study]. Ophthalmologe (2005) 0.75
[Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty]. Ophthalmologe (2007) 0.75
Gene regulation by steroid hormones. Cell (1989) 12.96
Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol (1992) 3.20
The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol (1992) 3.18
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem (1998) 2.85
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 2.67
Long-term graft survival after penetrating keratoplasty. Ophthalmology (2003) 2.53
Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci (2003) 1.69
Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol (1989) 1.67
Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology (1999) 1.66
Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology (2001) 1.64
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56
The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol (1989) 1.52
Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. Ophthalmology (1996) 1.42
Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology (1994) 1.26
Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol (2001) 1.23
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci (1993) 1.17
Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye (Lond) (1995) 1.17
Corticosteroids in 100 keratoplasties. Am J Ophthalmol (1969) 1.12
A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc (1990) 1.10
Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation (1996) 1.07
Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study. Ger J Ophthalmol (1992) 1.04
Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology (1991) 1.01
Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol (2002) 1.00
Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol (1999) 1.00
Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol (2003) 0.98
The effect of oral immunization on corneal allograft survival. Transplantation (1996) 0.97
Mechanisms of corneal graft failure: the erosion of corneal privilege. Eye (Lond) (1989) 0.96
Current practices in the prevention and treatment of corneal graft rejection. Cornea (1992) 0.96
Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. Pediatr Transplant (1999) 0.95
Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci (1997) 0.95
Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology (1993) 0.94
Corneal graft rejection: incidence, manifestation, and interaction of clinical subtypes. Transplant Proc (1992) 0.93
Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol (2000) 0.92
Adenovirus-mediated gene transfer of interleukin-4 to corneal endothelial cells and organ cultured corneas leads to high IL-4 expression. Exp Eye Res (1999) 0.91
Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation (1999) 0.91
Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci (1995) 0.91
[Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society]. Ophthalmologe (2003) 0.90
Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc (1989) 0.88
Current Australian practice in the prevention and management of corneal allograft rejection. Clin Experiment Ophthalmol (2000) 0.86
Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica (2002) 0.85
The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation (1993) 0.85
Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci (1993) 0.85
Corneal allograft rejection: current understanding. I. Immunobiology and basic mechanisms. Ophthalmologica (2001) 0.85
FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther (1996) 0.85
[Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results]. J Fr Ophtalmol (1987) 0.84
Topical FK-506 prevents experimental corneal allograft rejection. Cornea (1995) 0.84
Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol (1994) 0.84
The effect of corticosteroid and cyclosporin A on murine corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol (2000) 0.83
Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty. Ophthalmology (1992) 0.83
Outcome of penetrating keratoplasty in rheumatoid arthritis. Ophthalmologica (2002) 0.83
Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther (2003) 0.82
[Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance]. Ophthalmologe (2003) 0.82
Topical cyclosporin A in the management of postkeratoplasty glaucoma. Cornea (1997) 0.81
Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res (2001) 0.81
The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. Vet Res Commun (1998) 0.81
Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica (1996) 0.80
Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea (2002) 0.80
Kinetics of topically administered prednisolone acetate. Optimal concentration for treatment of inflammatory keratitis. Arch Ophthalmol (1976) 0.80
Gene therapy in immune-mediated diseases of the eye. Prog Retin Eye Res (2003) 0.79
A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. Cornea (1987) 0.79
Are cytokine patterns in aqueous humour useful in distinguishing corneal graft rejection from opacification due to herpetic stromal keratitis? Doc Ophthalmol (1999) 0.79
Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res (1994) 0.78
Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol (1994) 0.78
Primary graft failure caused by herpes simplex virus type 1. Cornea (2001) 0.78
[Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study]. Ophthalmologe (2002) 0.78
[Tissue typing in perforating corneal transplantation]. Ophthalmologe (2003) 0.78
Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. Ocul Immunol Inflamm (1999) 0.77
[Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease]. Klin Monbl Augenheilkd (2001) 0.77
[Herpes simplex keratitis. On the long-term prognosis of first transplants after penetrating keratoplasty]. Ophthalmologe (1993) 0.76
Promotion of corneal allograft survival with leflunomide. Invest Ophthalmol Vis Sci (1994) 0.75
Interleukin-2 receptor--targeted therapy by monoclonal antibodies in the rat corneal graft. Cornea (1994) 0.75
[Analysis of the aqueous humor in keratoplasty patients with keratitis. Initial results]. Ophthalmologe (2001) 0.75
Immune tolerance and gene therapy in transplantation. Immunol Today (2000) 0.75
[Comparison between local and systemic administration of cyclosporin A on the effective level in conjunctiva, aqueous humor and serum]. Ophthalmologe (1995) 0.75
Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today (1993) 0.75
The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol (1989) 0.75